Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProPhase Labs, Inc.PRPH · Entity 8699 | Director | February 14, 2025 | February 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProPhase Labs, Inc.
Report date February 14, 2025 · Filed February 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2032-02-14 | Direct | 100,000 |
Reported balance
After 2025-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-14 · Grant · Acquired 100,000 · Balance 100,000 F1: Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on each of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026 provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on each of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026 provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2025 Filed Feb 18, 2025 22:00 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001493152-25-007199 · ownership.xml · derivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on each of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026 provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date. Read SEC document |
| March 17, 2024 Filed Mar 20, 2024 01:49 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 70,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-24-010572 · ownership.xml · derivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-03-17 F1 · derivative.exercise_date: Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on each of September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date. Read SEC document |
| June 19, 2023 Filed Jun 21, 2023 20:15 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001493152-23-022007 · ownership.xml · derivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2023-06-18 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with such option vesting in four equal installments on September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024, provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of June 19, 2023. Read SEC document |
| June 16, 2023 Filed Jun 23, 2023 00:17 UTC Amendment | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001493152-23-022163 · ownership.xml · derivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock (the "Option"), with such option vesting in four equal installments on September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024, provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of June 16, 2023. F2 · derivative.expiration_date: This amended report on Form 4 is being filed to correct the Transaction Date and Expiration Date of the Option, which were inadvertently misreported in the original Form 4 filed on June 21, 2023. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 23:51 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $12.92 | $0.00 |
DisclosureSEC source: 0001493152-22-018603 · ownership.xml · derivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-07-01 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with such option vesting in four equal quarterly installments over one year, with the first quarterly installment to vest on September 30, 2022 and each additional installment to vest quarterly thereafter, provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of July 1, 2022. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 20:05 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001493152-21-014017 · ownership.xml · derivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-09 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with one-quarter of such stock option vesting on June 30, 2021 and the remaining portion vesting pro rata in equal monthly installments beginning July 31, 2021 and on the last day of each month thereafter, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of June 9, 2021. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 20:17 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001493152-20-017640 · ownership.xml · derivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-09-09 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with one-quarter of such stock option vesting on September 30, 2020 and the remaining portion vesting pro rata in equal monthly installments beginning October 31, 2020 and on the last day of each month thereafter, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of September 10, 2020. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:30 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | PurchaseCommon Stock, par value $0.0005 | 50,000 | $2.75 | $137,500.00 |
DisclosureSEC source: 0001493152-20-016097 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,840 F1 · shares: These shares were purchased in a private transaction from Ted Karkus, Chairman and Chief Executive Officer of the Issuer, pursuant to the terms of a Stock Purchase Agreement Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 17:32 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantCommon Stock, par value $0.0005 | 7,878 | $1.43 | $11,265.54 |
DisclosureSEC source: 0001493152-20-012453 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,840 F1 · shares: These shares of common stock were issued under the 2010 Directors' Equity Compensation Plan, as amended, pursuant to an election by the Reporting Person to receive shares of common stock of the Issuer in lieu of a cash payment for quarterly director fees. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 21:50 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantCommon Stock, par value $0.0005 | 6,068 | $1.85 | $11,225.80 |
DisclosureSEC source: 0001493152-20-005725 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,962 F1 · shares: These shares of common stock were issued under the 2010 Directors' Equity Compensation Plan, as amended, pursuant to an election by the Reporting Person to receive shares of common stock of the Issuer in lieu of a cash payment for quarterly director fees. Read SEC document |
| March 26, 2020 Filed Mar 27, 2020 23:17 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | PurchaseCommon Stock, par value $0.0005 | 100,000 | $1.75 | $175,000.00 |
DisclosureSEC source: 0001493152-20-004963 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,894 Read SEC document |
| January 01, 2020 Filed Jan 4, 2020 02:05 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantCommon Stock, par value $0.0005 | 5,564 | $2.02 | $11,239.28 |
DisclosureSEC source: 0001493152-20-000170 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,894 F1 · shares: These shares of common stock were issued under the 2010 Directors' Equity Compensation Plan, as amended, pursuant to an election by the Reporting Person to receive shares of common stock of the Issuer in lieu of a cash payment for quarterly director fees. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 22:44 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantCommon Stock, par value $0.0005 | 5,740 | $1.96 | $11,250.40 |
DisclosureSEC source: 0001493152-19-015007 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,330 F1 · shares: These shares of common stock were issued under the 2010 Directors' Equity Compensation Plan, as amended, pursuant to an election by the Reporting Person to receive shares of common stock of the Issuer in lieu of a cash payment for quarterly director fees. Read SEC document |
| July 01, 2019 Filed Aug 16, 2019 20:00 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantCommon Stock, par value $0.0005 | 4,727 | $2.38 | $11,250.26 |
DisclosureSEC source: 0001493152-19-012854 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,590 F1 · shares: These shares of common stock were issued pursuant to the terms of the 2010 Directors' Equity Compensation Plan, as amended, for director fees payable to non-employee directors. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 22:07 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantCommon Stock, par value $0.0005 | 3,571 | $3.15 | $11,248.65 |
DisclosureSEC source: 0001493152-19-004917 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,863 F1 · shares: These shares of common stock were issued pursuant to the terms of the 2010 Directors' Equity Compensation Plan, as amended, for director fees payable to non-employee directors. Read SEC document |
| January 02, 2019 Filed Jan 16, 2019 00:40 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantCommon Stock, par value $0.0005 | 3,583 | $3.14 | $11,250.62 |
DisclosureSEC source: 0001493152-19-000674 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,292 F1 · shares: These shares of common stock were issued pursuant to the terms of the 2010 Directors' Equity Compensation Plan, as amended, for director fees payable to non-employee directors. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 21:20 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantCommon Stock, par value $0.0005 | 3,737 | $3.01 | $11,248.37 |
DisclosureSEC source: 0001493152-18-014009 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,709 F1 · shares: These shares of common stock were issued pursuant to the terms of the 2010 Directors' Equity Compensation Plan, as amended, for quarterly director fees payable to non-employee directors. Read SEC document |
| July 19, 2018 Filed Jul 23, 2018 14:09 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantCommon Stock, par value $0.0005 | 3,737 | $3.01 | $11,248.37 |
DisclosureSEC source: 0001493152-18-010342 · ownership.xml · nonDerivative · entry 1 GLECKEL LOUIS MD · CIK 0001164762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,972 F1 · shares: These shares of common stock were issued pursuant to the terms of the 2010 Directors' Equity Compensation Plan, as amended, for quarterly director fees payable to non-employee directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.